Barclays Maintains Overweight on Sotera Health, Lowers Price Target to $20
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Barclays analyst Luke Sergott maintains Sotera Health (NASDAQ:SHC) with a Overweight and lowers the price target from $22 to $20.
Barclays analyst Luke Sergott maintains Sotera Health (NASDAQ:SHC) with a Overweight and lowers the price target from $22 to $20.